Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Surgical Oncology, Claudius Regaud Comprehensive Cancer Center, Toulouse, France.
J Minim Invasive Gynecol. 2014 Jan-Feb;21(1):3-8. doi: 10.1016/j.jmig.2013.07.007. Epub 2013 Jul 31.
Radiation treatment planning for women with locally advanced cervical cancer (stages IB2-IVA) is often based on positron emission tomography (PET). PET, however, has poor sensitivity in detecting metastases in aortocaval nodes. We have initiated a study with the objective of determining whether pre-therapeutic laparoscopic surgical staging followed by tailored chemoradiation improves survival as compared with PET/computed tomography (CT) radiologic staging alone followed by chemoradiation. This international, multicenter phase III trial will enroll 600 women with stages IB2-IVA cervical cancer and PET/CT findings showing fluorodeoxyglucose-avid pelvic nodes and fluorodeoxyglucose-negative para-aortic nodes. Eligible patients will be randomized to undergo either pelvic radiotherapy with chemotherapy (standard-of-care arm) or surgical staging via a minimally invasive extraperitoneal approach followed by tailored radiotherapy with chemotherapy (experimental arm). The primary end point is overall survival. Secondary end points are disease-free survival, short- and long-term morbidity with pre-therapeutic surgical staging, and determination of anatomic locations of metastatic para-aortic nodes in relationship to the inferior mesenteric artery. We believe this study will show that tailored chemoradiation after pre-therapeutic surgical staging improves survival as compared with chemoradiation based on PET/CT in women with stages IB2-IVA cervical cancer.
局部晚期宫颈癌(IB2-IVA 期)患者的放射治疗计划通常基于正电子发射断层扫描(PET)。然而,PET 在检测腹主动脉旁淋巴结转移方面的敏感性较差。我们已经启动了一项研究,旨在确定与单独进行基于 PET/计算机断层扫描(CT)的放射影像学分期后进行放化疗相比,术前腹腔镜外科分期后进行个体化放化疗是否能提高生存。这项国际多中心 III 期试验将招募 600 名 IB2-IVA 期宫颈癌且 PET/CT 检查显示氟脱氧葡萄糖摄取的盆腔淋巴结和氟脱氧葡萄糖阴性的腹主动脉旁淋巴结的患者。符合条件的患者将被随机分为接受盆腔放疗联合化疗(标准治疗组)或通过微创经腹腔途径进行外科分期后接受个体化放疗联合化疗(实验组)。主要终点是总生存。次要终点是无病生存、术前外科分期的短期和长期发病率以及确定与肠系膜下动脉相关的腹主动脉旁转移性淋巴结的解剖位置。我们相信这项研究将表明,与基于 PET/CT 的放化疗相比,术前个体化放化疗可改善局部晚期宫颈癌(IB2-IVA 期)患者的生存。